Skip to main content
. 2020 Feb 18;7:11. doi: 10.3389/fmed.2020.00011

Figure 4.

Figure 4

Results (in percentage) of different screening steps according to final patients' classification. *Statistical significance <0.025 for post-hoc analysis. MSA/MAA, myositis specific antibodies/myositis associated antibodies; RF, rheumatoid factor; anti-CPP, anti-cyclic citrullinated peptide antibodies; NVC, nailfold videocapillaroscopy.